San Diego-based biopharmaceutical company KymaThera has successfully closed an $80 million Series B financing round to propel its lead oncology…
Read More

San Diego-based biopharmaceutical company KymaThera has successfully closed an $80 million Series B financing round to propel its lead oncology…
Read More
The global burden of head and neck squamous cell carcinoma (HNSCC) is on an upward trajectory, with an estimated increase…
Read More